Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, has been awarded the 2026 Biotech Breakthrough Award for Cancer Immunology Solution of the Year for its investigational therapy ENV-105 (carotuximab). The recognition underscores the company's innovative approach to restoring the effectiveness of existing cancer treatments in metastatic prostate cancer and non-small cell lung cancer, two areas with significant unmet need.
ENV-105 is a neutralizing antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By blocking CD105, ENV-105 aims to reverse drug resistance and re-sensitize tumors to standard-of-care therapies. The award comes on the heels of positive interim efficacy data from an ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. The interim analysis demonstrated a statistically significant difference in progression-free survival between patients receiving the combination therapy and those receiving apalutamide alone, a finding that could have profound implications for treatment paradigms.
The Biotech Breakthrough Award recognition is more than an accolade; it signals validation of Kairos Pharma's structural biology-based approach to overcoming immune suppression and drug resistance. If ENV-105 continues to show benefit in later-stage trials, it could offer a new therapeutic option for patients whose cancers have become resistant to conventional treatments. The potential to extend progression-free survival in prostate cancer, and possibly in non-small cell lung cancer, represents a meaningful step forward in oncology. For investors, the award and the interim data may enhance the company's visibility and credibility in the competitive biotech landscape. As a clinical-stage company, Kairos Pharma's progress with ENV-105 will be closely watched, and the recognition may help attract further attention to its pipeline.
To view the full press release, visit https://ibn.fm/GnUxn. The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The award and data could also impact the broader conversation around cancer immunology, as researchers and clinicians seek ways to combat resistance. Kairos Pharma's focus on CD105 as a target may inspire further investigation into similar mechanisms across other cancer types. With the interim data and award in hand, the company is positioned to potentially accelerate its development plans and partnerships. However, as with any clinical-stage therapy, risks remain, and the final results of the Phase 2 trial will be critical. Nonetheless, the recognition highlights the importance of innovative approaches to cancer treatment and the potential of ENV-105 to make a difference in patients' lives.
